|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2001-9-11
|
|
pubmed:abstractText |
Mobilised peripheral blood stem cells are widely used for autografting in patients with chronic myeloid leukaemia (CML) and it is generally thought that a high proportion of Ph-negative progenitor cells in the graft is desirable. We report here the results of 91 stem cell mobilisations performed with various chemotherapy regimens followed by G-CSF. We show that mobilisation of Ph-negative cells is possible after diagnosis as well as in advanced stages of the disease. The yield of Ph-negative cells is highly dependent on the chemotherapy regimen: while the combination of idarubicin and cytarabin for 3-5 days (IC3-5) mobilised Ph-negative cells in most patients, high-dose cyclophosphamide was ineffective. Mobilisation of Ph-negative progenitor cells after IC3 was at least as effective as after IC5; however, less apheresis sessions were required, and toxicity was much reduced after IC3. Compared to historical controls, IC was equally effective as the widely used ICE/miniICE (idarubicin, cytarabin, etoposide) protocol. No correlation was found between graft quality and the cytogenetic response to subsequent treatment with interferon-alpha. We conclude that IC3 is an effective and well-tolerated regimen for mobilising Ph-negative cells that compares well with more aggressive approaches such as IC5 and ICE/miniICE.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0268-3369
|
|
pubmed:author |
pubmed-author:DölkenGG,
pubmed-author:DachseltKK,
pubmed-author:DeiningerMM,
pubmed-author:DoepperJJ,
pubmed-author:East German Study Group Haematology/Oncology (OSHO),
pubmed-author:EdenKK,
pubmed-author:FiedlerFF,
pubmed-author:FrankeAA,
pubmed-author:FreundMM,
pubmed-author:HelbigWW,
pubmed-author:HeroldMM,
pubmed-author:HoffmannF AFA,
pubmed-author:KettnerEE,
pubmed-author:KragtKK,
pubmed-author:LangeTT,
pubmed-author:LeibleinSS,
pubmed-author:NiederwieserDD,
pubmed-author:PönischWW,
pubmed-author:PasoldRR,
pubmed-author:RichterPP,
pubmed-author:SchultzeWW,
pubmed-author:SchwalbeEE,
pubmed-author:SchwarzerAA,
pubmed-author:SteglichJJ,
pubmed-author:SubertRR,
pubmed-author:UhleRR,
pubmed-author:WinkelmannCC,
pubmed-author:von GrünhagenUU
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1125-32
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11551022-Adolescent,
pubmed-meshheading:11551022-Adult,
pubmed-meshheading:11551022-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11551022-Cyclophosphamide,
pubmed-meshheading:11551022-Cytarabine,
pubmed-meshheading:11551022-Female,
pubmed-meshheading:11551022-Graft Survival,
pubmed-meshheading:11551022-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:11551022-Hematopoietic Stem Cell Mobilization,
pubmed-meshheading:11551022-Humans,
pubmed-meshheading:11551022-Idarubicin,
pubmed-meshheading:11551022-Interferon-alpha,
pubmed-meshheading:11551022-Leukapheresis,
pubmed-meshheading:11551022-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:11551022-Male,
pubmed-meshheading:11551022-Middle Aged,
pubmed-meshheading:11551022-Philadelphia Chromosome
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Chemotherapy for mobilisation of Ph-negative progenitor cells from patients with CML: impact of different mobilisation regimens.
|
|
pubmed:affiliation |
Department of Hematology, University of Leipzig, Germany.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study
|
